Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Study of 10 million men finds many are having prostate cancer tests more frequently than recommended. Research published in The BMJ reveals significant variations in PSA testing across England, raising concerns about overtesting.

A man is filling in a prostate specific antigen (PSA) test

New research lead by Oxford Cancer DPhil in Cancer Science student reveals significant variations in how prostate specific antigen (PSA) tests are used in English primary care, with many men being tested more frequently than recommended.

“PSA testing in primary care is varied,” says Kiana Collins, DPhil student and lead author based in the Nuffield Department of Primary Care Health Sciences. “Among patients who underwent multiple tests, many were tested more frequently than recommended, raising concerns about overtesting. PSA retesting is occurring in patients without recorded symptoms or with previous low PSA values.”

The study, published in The BMJ, analysed data from over 10 million men registered at GP practices across England between 2000 and 2018. The findings raise important questions about how PSA testing is being used and whether current approaches effectively target those most likely to benefit.

Almost half of those tested were retested at least once, yet more than 70% never had a PSA value above the age-specific threshold that would typically prompt a referral to specialist care. The median time between tests was around 12.5 months – shorter than most international guidance recommends, and much shorter than would be expected for lower-risk men.

Testing rates were highest in men aged 70 and older – a group least likely to benefit from repeat testing and most at risk of overdiagnosis. Researchers estimate that men in this age group account for around 40% of prostate cancer overdiagnoses.

 

Read the full story on the Nuffield Department of Primary Care Health Sciences website.

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience